

Tirzepatide in community settings
From 23 June, some people living with obesity may be eligible to access tirzepatide (Mounjaro®) for weight loss purposes in community settings as outlined in NICE guidelines. Access is prioritised for those with the greatest clinical need (see page 7 of the interim commissioning guidance for eligibility criteria).
Initially, only a small number of people are eligible, including those people living with obesity, in poor health with multiple obesity related conditions, as they are likely to benefit most from the treatment.
Access routes and services will differ across each ICB. Clinicians will need to await details from their ICB on the weight management pathway in the community. This will include pathways for prescribing as well as referring into a ‘wraparound’ offer.
A communications toolkit is available to support with communicating about how tirzepatide will be implemented locally.
Related Posts
Seasonal Vaccinations Site Campaign Guide AW24
NHS England has published The Seasonal Vaccinations Site Campaign Guide for AW24 that outlines the key guidance and activities required…
GPC England has voted to accept the proposed contract for 2025-26 with contingency
GPC England has agreed in principle to accept proposed amendments to the 2025/26 GP GMS contract following two months of…
BMA Local Event – Resilience and Well-Being for Doctors
Doctors experience difficult and emotionally challenging situations in the front line of healthcare. It is therefore crucial that the inherent…